Clinical Study
The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
Table 1
Baseline characteristics.
| | Patients with of PV | Total |
| | Age at recruitment | 64.6 (11.8) | | Sex (Males) | 198 (62.1) | | Years from diagnosis to enrollment | 4.4 (5.5) | | 0ā2 | 146 (45.8) | | 3ā5 | 69 (21.6) | | 6ā10 | 64 (20.1) | | >10 | 40 (12.5) |
| | Hematology | | | Hb g/dL* | 15.2 (1.7) | | HCT %* | 47.2 (4.6) | | Platelets 10(6)/mm3 | 402 (184) | | RBC 10(6)/mm3 | 5.7 (1.1) | | WBC 10(3)/mm3 | 10.6 (14.9) |
| | Clinical chemistry | | | Total cholesterol mg/dL | 173.1 (41.2) | | HDL-cholesterol mg/dL | 47.7 (14.2) | | LDL-cholesterol mg/dL | 99.2 (31.6) | | Fasting blood glucose mg/dL | 94.1 (22.8) |
| | Prior cardiovascular events | | | Prior thrombosis | 99 (31.2) | | Arterial | 59 (18.6) | | āAMI | 27 (8.6) | | āStroke | 10 (3.1) | | āTIA | 14 (4.4) | | āPAT | 2 (0.6) | | āExtremities | 5 (1.6) | | āOther | 2 (0.6) | | Venous | 43 (13.6) | | āPE | 5 (1.6) | | āDVT | 21 (6.6) | | āSVT | 14 (4.4) | | āOther | 11 (3.5) | | Arterial and venous | 4 (1.3) |
| | Prior haemorrhagic Events | 16 (5.1) | | Major bleeding | 6 (1.9) | | āBrain | 1 (0.3) | | āStroke | 0 (0.0) | | āGI | 4 (1.3) | | Minor bleeding | 10 (3.1) | | Erythromelalgia | 17 (5.4) |
| | Cardiovascular risk factors and comorbidity | | | Hypertension | 175 (55.2) | | Hypercholesterolemia | 55 (17.4) | | Diabetes mellitus | 29 (9.2) | | Current smoker | 32 (10.1) | | Claudicatio intermittent | 2 (0.6) | | Coronary arterial disease | 29 (9.1) |
| | Management of PV disease | | | Phlebotomy | 261 (82.3) | | AntiPLT | 266 (83.9) | | āAspirin | 243 (76.7) | | Anticoagulant | 41 (12.9) | | Hydroxyurea | 167 (52.7) | | 32P | 0 (0.0) | | Busulphan | 2 (0.6) | | Chorambucil | 0 (0.0) | | Pipobroman | 14 (4.4) | | Interferon | 7 (2.2) | | JAK2 inhibitors | 0 (0.0) | | Anagrelide | 0 (0.0) | | Other cytoreductive drugs | 3 (1.0) |
| | Treatments for CV risk factors | | | Hypocholesterolemic medication | 43 (13.6) | | Anti diabetic medication | 16 (5.1) | | Anti hypertensive medication | 153 (48.3) |
| | Cytogenetics | | | Jak2 V617F (positive) | 307 (96.9) | | āJak2 V617F (%) | 50.0 (27.6) | | Jak2 V617F (negative) | 10 (3.2) | | Jak2 Exon12 (positive) | 5 (1.6) | | Jak2 Exon12 (negative) | 18 (5.7) |
|
|
